Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How Novo Nordisk Built a Board That Balanced Science and Scale
Transcript
- Lucas: So Novo Nordisk is now the most valuable company in Europe. Market cap north of five hundred billion dollars, all driven by one drug class — semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss. But what‘s interesting to me isn’t just the sales numbers. It‘s how the board managed to scale a scientific bet into a global blockbuster without losing the company’s research soul. Luna: And that‘s not easy. Most pharma companies that hit a blockbuster either get bought, or they pivot to pure marketing and the pipeline dries up. Novo hasn’t done that. So what‘s different about how their board operates? Lucas: The single biggest structural difference is the ownership. Novo Nordisk is controlled by the Novo Nordisk Foundation, which owns about 77 percent of the voting shares. The foundation‘s charter mandates that it reinvests its returns into medical research and charitable causes. That means the board isn’t answering to quarterly hedge funds. It answers to a mission. Luna: Right, so the foundation acts almost like a permanent steward. That changes the time horizon entirely. Lucas: Exactly. The board can approve a research program that might not pay off for a decade. And they did exactly that with semaglutide. The molecule was first synthesized in 1997. The GLP-1 mechanism was known since the 1980s. But it took Novo twenty years of clinical work to turn it into a commercial product. No public-market board would have tolerated that timeline without demanding a pivot. Luna: So the foundation structure gives them patience. But patience alone doesn‘t explain the execution. How did the board ensure that the company actually delivered on the science? Lucas: This is where the two-tier board system matters. Denmark uses a supervisory board and a management board. The supervisory board, which includes the foundation representatives and independent members, sets the long-term strategy. The management board runs day-to-day operations. But the key is that the supervisory board has deep scientific expertise. For years, the chair was Göran Ando, a physician and former pharma executive. The current chair, Helge Lund, isn’t a scientist himself, but he’s surrounded by board members with hard science backgrounds. Luna: So they can actually evaluate the pipeline critically, not just trust management‘s say-so. Lucas: Precisely. In 2014, when the early data on semaglutide for weight loss came in, the board didn’t just greenlight a marketing campaign. They had the internal expertise to push for an aggressive cardiovascular outcomes trial — the kind that regulators and insurers require before they‘ll approve a drug for chronic weight management. That trial cost hundreds of millions and took years. A less knowledgeable board might have balked. Luna: And that trial was what ultimately made Wegovy a blockbuster. The SELECT trial showed a twenty percent reduction in major cardiovascular events. That was the data that convinced insurers to cover it. Lucas: Exactly. So the board didn’t just approve a budget. It directed management toward a strategic decision that made the drug much more valuable, but also much more expensive to develop. That‘s governance with actual substance. Luna: And then, when the drug hit, the board faced a completely different challenge — scaling supply. Ozempic and Wegovy shortages lasted for over a year. How did they handle that? Lucas: This is where I think the board showed real discipline. They could have pushed management to outsource manufacturing to third parties, which would have increased short-term supply but risked quality control. Instead, they stuck with Novo‘s internal manufacturing model, which is notoriously slow and expensive but highly reliable. They approved massive capital expenditure for new facilities in Denmark and the US, with a multiyear horizon. Short-term revenues took a hit from shortages, but the board prioritized long-term brand trust. Luna: Speaking of trust — let’s talk about pricing. In 2023, Novo Nordisk announced it would cap insulin prices at $25 per month in the US. That was a board-level decision, right? Lucas: Almost certainly. Insulin is a tiny part of their revenue now — semaglutide dwarfs it. But insulin pricing has been a reputational nightmare for the entire industry. By capping prices unilaterally, the board signaled that they weren‘t going to squeeze every dollar out of a drug that patients literally need to survive. It was a strategic move to preserve the company’s social license, and it only works because the foundation board doesn‘t have to worry about a quarterly earnings miss spooking investors. Luna: And it stands in stark contrast to how other pharma companies have handled insulin pricing. Eli Lilly and Sanofi eventually followed, but Novo led. Lucas: Right. And that leads to a broader point. The Novo board has been willing to accept lower profit margins on legacy products in exchange for long-term trust. That‘s a calculus that most public company boards can’t make because their shareholders demand margin expansion every quarter. Luna: I want to push back a little though. Isn‘t this structure also a risk? A foundation with controlling voting power — that’s essentially an unelected group with immense influence. What if they make bad decisions? Lucas: It‘s a real risk, and it’s not hypothetical. The foundation is run by a board of its own, appointed by the Danish government and the foundation‘s own members. There’s no proxy fight, no activist investor to swoop in if the company underperforms. So the governance relies heavily on the quality of the people. And there have been stumbles. In the 1990s, Novo diversified into industrial enzymes and even food ingredients — a strategy that diluted focus. It took years to unwind. Luna: So the board can make mistakes without external accountability. Lucas: In the short term, yes. But the foundation structure also forces the board to think about the company‘s survival over decades, not years. That’s why they‘ve been able to invest in areas like gene editing and cell therapy, which won’t pay off for fifteen years if they pay off at all. A typical pharma board would have divested those units long ago. Luna: Before we go deeper, this is actually something that a lot of our listeners have written in about — how do you sustain long-term thinking when the market is constantly pressuring for short-term results? And I think the example we‘re discussing today shows that structure really matters. If these conversations have moved your work forward in some small way, we hope you’ll consider supporting the show. A couple of dollars a month is genuinely what keeps these going — buy me a coffee dot com slash fexingo, if you‘ve gotten something out of them. Lucas: Yeah, it’s listener support that keeps us ad-free and lets us dive into these deep governance stories. Appreciate it. Luna: Alright, so back to the board. One area where I think the Novo board has been particularly smart is in how they‘ve handled the Ozempic hype. There’s been enormous pressure to expand indications and push into new markets quickly. How did the board manage that? Lucas: They‘ve been cautious. The board approved a clinical program for semaglutide in heart failure, chronic kidney disease, and even Alzheimer’s. But they‘ve been disciplined about not over-promising. They let the data drive the timeline, not the stock price. That’s rare in biotech. Luna: And they‘ve also been careful about manufacturing capacity allocation between Ozempic and Wegovy. They didn’t rob from diabetes to feed weight loss, even though weight loss is the bigger market. Lucas: Right. That was another board-level trade-off. They could have shifted production entirely to Wegovy and captured more revenue, but they maintained supply for diabetes patients first. That‘s a decision that only makes sense if you’re playing the very long game. Luna: So what can other pharma boards learn from Novo? Let‘s say you’re on the board of a mid-cap biotech that‘s about to launch a blockbuster. What do you take away? Lucas: First, build scientific expertise on the board itself. Not just one doctor on the audit committee — real depth. Second, be willing to invest in manufacturing capacity before you know the drug will succeed. That’s counterintuitive because it‘s expensive and risky, but it’s what allowed Novo to scale quickly when demand exploded. Third, have a clear position on pricing and access before the media forces you to have one. Luna: And the foundation structure — is that replicable? Most companies can‘t just create a controlling foundation overnight. Lucas: It’s not directly replicable, but the principle is. You can cultivate a shareholder base that‘s aligned with long-term value. That means attracting institutional investors with long horizons, like pension funds and sovereign wealth funds, and communicating a clear strategy that doesn’t cater to short-term traders. The Novo board does that extremely well. They publish detailed annual reports on their research pipeline with ten-year outlooks. They treat investors as partners, not spectators. Luna: One last thing — succession. The CEO Lars Fruergaard Jørgensen has been in the role since 2017. How does the board think about his eventual replacement? Lucas: That‘s a great question. The board has been grooming internal candidates for years. Novo has a very deep management bench, partly because the foundation structure allows them to retain talent without worrying about stock-based compensation cliffs. The board’s succession committee meets regularly, and they‘ve been transparent about the process. They’re not going to hire an outsider just for a fresh perspective. They‘ll promote from within, which preserves the culture. Luna: So the board essentially treats CEO succession as a long-term development process, not a crisis event. Lucas: Exactly. And that’s the through-line for everything we‘ve discussed today. The Novo Nordisk board operates with a time horizon that most boards can only imagine. They don’t have to choose between doing good science and making money, because the structure lets them do both over decades. It‘s not a perfect model — no governance system is — but it’s a compelling example of how board design can shape corporate destiny. Luna: And it‘s why Novo is now the most valuable company in Europe. Not despite its governance, but because of it. Lucas: Exactly. Next time we’ll look at a board that had the opposite problem — one that let short-term thinking destroy long-term value. Until then.